Clinical Trial: Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds

U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07717736) titled 'Phase 4 Master Protocol for Patients Prescribed Prademagene Zamikeracel for the Treatment of Wounds' on July 16.

Brief Summary: The Master Protocol includes 3 studies (Study A, Study B, and Study C) that will evaluate pz-cel and related processes in the post-marketing setting.

Study A investigates the efficacy and safety of non-conforming pz-cel in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Study B enables the collection of additional biopsy samples from patients receiving treatment with pz-cel.

Study C assesses the efficacy and safety of pz-cel in patient populations not represented in the VIITAL clinical t...